Tevogen Bio

Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T-cell therapies for the treatment of infectious diseases and cancer. The firm's proprietary ExacTcell platform harnesses the power of cytotoxic T lymphocytes (CTLs) to create scalable and rapidly producible treatments.

The company's approach focuses on developing therapeutic products that are designed to be accessible and affordable, targeting a broad range of patients. Tevogen Bio is currently advancing its pipeline of product candidates for various viral infections and cancers, leveraging its expertise in cell and gene therapy. As a publicly-traded entity, its business model is centered on the research, clinical development, and eventual commercialization of its immunotherapies.

Keywords: immunotherapy, T-cell therapy, oncology, infectious diseases, biotechnology, cell therapy, gene therapy, clinical-stage, cytotoxic T lymphocytes, ExacTcell